Three sites, one quality system.
Our manufacturing spans India and Oman. Puducherry is in production, Sanand is being built for scale, and Oman will formulate and fill for global markets. Together they cover the full chain, from drug substance to finished cartridge.
Our sites.
Sanand, Gujarat, India
Under construction; commercial 2028 (planned)
Khazaen Economic City, Oman
Under development; commercial 2029 (planned)
Our operating site, being upgraded to global standards.
Our Puducherry plant stands on a 20,500 square-metre site. It makes drug substance, finished product and clinical supplies for all three insulin analogues, as well as our recombinant enzymes.
The plant is WHO-GMP certified and is being upgraded to EU-GMP and PIC/S standards, ahead of our European filing.
20,500 m² siteWHO-GMP certifiedBeing upgraded to EU-GMP and PIC/SDrug substance · finished product · clinical supplies
Built for scale.
Our Sanand facility in Gujarat, on a ~40,000 square-metre site, will make drug substance and finished product (fill-finish) at commercial scale. It is designed to the Standard of the European Medicine Agency, WHO and to ICH guidelines.
~40,000 m² siteDrug substance · fill-finishCommercial 2028 (planned)EMA · WHO · ICH
Fill-finish for global markets.
Our subsidiary, BioGenomics International SPC, is building a formulation and fill-finish facility on a 23,000 square-metre site at Khazaen Economic City, Oman.
The facility targets compliance with the Ministry of Health of Oman (MOH Oman), the European Medicines Agency (EMA) and the Saudi Food and Drug Authority (SFDA). Commercial operation is planned for 2029.
23,000 m² siteCommercial 2029 (planned)MOH Oman · EMA · SFDA
Every cartridge must be one a doctor can trust.
One quality system governs every site, every batch and every release. It covers:
- Batch testing and release against approved specifications.
- Change control and deviation management.
- Data integrity.
- Qualification of facilities, equipment and suppliers.
- Internal audits and regulatory inspections.
Supply you can rely on.
At least three qualified suppliers for every critical material.
For every critical raw material and component, we qualify at least three suppliers. Each is audited, approved and bound by a quality agreement.
If one supplier fails, production continues. A person on insulin cannot wait for a shortage to resolve.
A managed chain, from India to the world.
Drug substance and finished product are made in India: at Puducherry today and, from 2028, also at Sanand. From 2029, Oman adds formulation and fill-finish. When both new sites are complete, every product will have at least two sources of drug substance and of fill-finish.
Today
Drug substance and fill-finish at Puducherry.
2028
Sanand adds drug substance and fill-finish.
2029
Oman adds fill-finish.
Then
At least two sources of drug substance and of fill-finish for every product.